Remove Engineering Remove Immune Response Remove Protein Expression
article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

article thumbnail

A therapy candidate for fatal prion diseases turns off disease-causing gene

Broad Institute

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

mRNA Cancer Vaccines mRNA cancer vaccines represent a newer class of vaccines utilizing mRNA’s ability to encode for almost any protein, while maintaining an acceptable safety profile with flexible delivery and production processes. Monoclonal Antibodies Monoclonal antibodies are lab-engineered immune system proteins.

Vaccine 52
article thumbnail

Codon Digest: CAR-T Therapy for Neuroblastoma

Codon

LanzaTech announced a partnership with H&M Move to convert factory carbon emissions into fabrics using engineered microbes. Sponge cells double in population quite quickly — around 40 minutes — and could be engineered to manufacture drugs. Read Biological Engineering *Self-healable spider dragline silk materials.

article thumbnail

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

The Pharma Data

In addition, the observed median PFS shows that the regimen can induce a sustained and durable response, which is also shown consistently by the induction of a specific immune response. Conclusions. More information on the trial is available on clinicaltrials.gov. About TG4001.

Vaccine 40